Short- and long-term effects of prenatal exposure to iron oxide nanoparticles: Influence of surface charge and dose on developmental and reproductive toxicity

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 30251-30268

  Di Bona, Kristin R ^a   Xu, Yaolin ^b   Gray, Marquita ^a   Fair, Douglas ^a   Hayles, Hunter ^a   Milad, Luckie ^a   Montes, Alex ^a   Sherwood, Jennifer ^b   Bao, Yuping ^b   Rasco, Jane F ^a  

^a UNIVERSITY OF ALABAMA   (United States)

^b University of Alabama   (United States)

Author keywords

Developmental toxicity; Fetotoxicity; Iron oxide; Nanoparticles; Nanotoxicity; Surface charge

Indexed keywords

ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; FERRIC ION; FERRIC OXIDE; NANOPARTICLE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CONCEPTION; CONTROLLED STUDY; FEMALE; FERTILITY; FETUS WASTAGE; FETUS WEIGHT; HISTOPATHOLOGY; MOUSE; NONHUMAN; PREGNANCY; PRENATAL EXPOSURE; REPRODUCTIVE TOXICITY; WEIGHT GAIN; ANIMAL; CESAREAN SECTION; DRUG EFFECTS; EMBRYO DEVELOPMENT; FETUS; LITTER SIZE; MALE; PATHOLOGY; REPRODUCTION; SURFACE PROPERTY; TESTIS; TIME FACTOR; UTERUS;

ANIMALS; CESAREAN SECTION; EMBRYONIC DEVELOPMENT; FEMALE; FERRIC COMPOUNDS; FERTILITY; FETUS; LITTER SIZE; MALE; MICE; NANOPARTICLES; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REPRODUCTION; SURFACE PROPERTIES; TESTIS; TIME FACTORS; UTERUS;

EID: 84950125702     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226231     Document Type: Article

References (46)

1. Elsaesser, A.; Howard, C.V. Toxicology of nanoparticles. Adv. Drug Deliv. Rev. 2012, 64, 129-137. [CrossRef] [PubMed].
2. United States Government Accountability Office. Nanotechnology: Nanomaterials are widely used in commerce, but EPA faces challenges in regulating risk. Int. J. Occup. Environ. Health 2010, 16, 525-539.
3. Valdiglesias, V.; Kilic, G.; Costa, C.; Fernandez-Bertolez, N.; Pasaro, E.; Teixeira, J.P.; Laffon, B. Effects of iron oxide nanoparticles: Cytotoxicity, genotoxicity, developmental toxicity, and neurotoxicity. Environ. Mol. Mutagen. 2015, 56, 125-148. [CrossRef] [PubMed].
4. Pankhurst, Q.A.; Connolly, J.; Jones, S.K.; Dobson, J. Applications of magnetic nanoparticles in biomedicine. J. Phys. D Appl. Phys. 2003, 36, 167-181. [CrossRef].
5. Hubbell, J.A.; Chilkoti, A. Nanomaterials for drug delivery. Science 2012, 337, 303-305. [CrossRef] [PubMed].
6. Haider, A.; Kang, I.K. Preparation of silver nanoparticles and their industrial and biomedical applications: A comprehensive review. Adv. Mater. Sci. Eng. 2015, 2015. Available online: http://dx.doi.org/10.1155/2015/165257 (accessed on 14 December 2015). [CrossRef].
7. Stark, W.; Stoessel, P.; Wohlleben, W.; Hafner, A. Industrial applications of nanoparticles. Chem. Soc. Rev. 2015, 44, 5793-5805. [CrossRef] [PubMed].
8. Reimer, P.; Balzer, T. Ferucarbotran (Resovist): A new clinically approved res-specific contrast agent for contrast-enhanced MRI of the liver: Properties, clinical development, and applications. Eur. Radiol. 2003, 13, 1266-1276. [PubMed].
9. Namdeo, M.; Saxena, S.; Tankhiwale, R.; Bajpai, M.; Mohan, Y.M.; Bajpai, S.K. Magnetic nanoparticles for drug delivery applications. J. Nanosci. Nanotechnol. 2008, 8, 3247-3271. [CrossRef] [PubMed].
10. Xie, J.; Huang, J.; Li, X.; Sun, S.; Chen, X. Iron oxide nanoparticle platform for biomedical applications. Curr. Med. Chem. 2009, 16, 1278-1294. [CrossRef] [PubMed].
11. Gupta, A.K.; Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26, 3995-4021. [CrossRef] [PubMed].
12. Alam, S.R.; Shah, A.S.V.; Richards, J.; Lang, N.N.; Barnes, G.; Joshi, N.; MacGillivray, T.; McKillop, G.; Mirsadraee, S.; Payne, J.; et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction early clinical experience. Circ. Cardiovasc. Imaging 2012, 5, 559-565.
13. Lu, M.; Cohen, M.H.; Rieves, D.; Pazdur, R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 2010, 85, 315-319. [CrossRef] [PubMed].
14. Karn, B.; Kuiken, T.; Otto, M. Nanotechnology and in situ remediation: A review of the benefits and potential risks. Environ. Health Perspect. 2009, 117, 1823-1831. [CrossRef] [PubMed].
15. Dickinson, M.; Scott, T.B. The application of zero-valent iron nanoparticles for the remediation of a uranium-contaminated waste effluent. J. Hazard. Mater. 2010, 178, 171-179. [CrossRef] [PubMed].
16. Li, X.Q.; Elliott, D.W.; Zhang,W.X. Zero-valent iron nanoparticles for abatement of environmental pollutants: Materials and engineering aspects. Crit. Rev. Solid State Mater. Sci. 2006, 31, 111-122. [CrossRef].
17. Zhang, W.X. Nanoscale iron particles for environmental remediation: An overview. J. Nanopart. Res. 2003, 5, 323-332. [CrossRef].
18. Mueller, N.C.; Nowack, B. Nanoparticles for remediation: Solving big problems with little particles. Elements 2010, 6, 395-400. [CrossRef].
19. Sharifi, S.; Behzadi, S.; Laurent, S.; Forrest, M.L.; Stroeve, P.; Mahmoudi, M. Toxicity of nanomaterials. Chem. Soc. Rev. 2012, 41, 2323-2343. [CrossRef] [PubMed].
20. Li, Y.; Zhang, Y.; Yan, B. Nanotoxicity overview: Nano-threat to susceptible populations. Int. J. Mol. Sci. 2014, 15, 3671-3697. [CrossRef] [PubMed].
21. Teske, S.S.; Detweiler, C.S. The biomechanisms of metal and metal-oxide nanoparticles' interactions with cells. Int. J. Environ. Res. Public Health 2015, 12, 1112-1134. [CrossRef] [PubMed].
22. Menezes, V.; Malek, A.; Keelan, J.A. Nanoparticulate drug delivery in pregnancy: Placental passage and fetal exposure. Curr. Pharm. Biotechnol. 2011, 12, 731-742. [CrossRef] [PubMed].
23. Kulvietis, V.; Violeta, Z.; Janina, D.; Ricardas, R. Transport of nanoparticles through the placental barrier. Tohoku J. Exp. Med. 2011, 225, 225-234. [CrossRef] [PubMed].
24. Wigle, D.T.; Arbuckle, T.E.; Turner, M.C.; Berube, A.; Yang, Q.Y.; Liu, S.L.; Krewski, D. Epidemiologic evidence of relationships between reproductive and child health outcomes and environmental chemical contaminants. J. Toxicol. Environ. Health Part B Crit. Rev. 2008, 11, 373-517. [CrossRef] [PubMed].
25. Saunders, M. Transplacental transport of nanomaterials. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1, 671-684. [CrossRef] [PubMed].
26. Takeda, K.; Suzuki, K.I.; Ishihara, A.; Kubo-Irie, M.; Fujimoto, R.; Tabata, M.; Oshio, S.; Nihei, Y.; Ihara, T.; Sugamata, M. Nanoparticles transferred from pregnant mice to their offspring can damage the genital and cranial nerve systems. J. Health Sci. 2009, 55, 95-102. [CrossRef].
27. Yoshida, S.; Hiyoshi, K.; Oshio, S.; Takano, H.; Takeda, K.; Ichinose, T. Effects of fetal exposure to carbon nanoparticles on reproductive function in male offspring. Fertil. Steril. 2010, 93, 1695-1699. [CrossRef] [PubMed].
28. Park, E.-J.; Kim, H.; Kim, Y.; Park, K. Effects of platinum nanoparticles on the postnatal development of mouse pups by maternal exposure. Environ. Health Toxicol. 2010, 25, 279-286.
29. Di Bona, K.R.; Xu, Y.; Ramirez, P.A.; DeLaine, J.; Parker, C.; Bao, Y.; Rasco, J.F. Surface charge and dosage dependent potential developmental toxicity and biodistribution of iron oxide nanoparticles in pregnant cd-1 mice. Reprod. Toxicol. 2014, 50, 36-42. [CrossRef] [PubMed].
30. Noori, A.; Parivar, K.; Modaresi, M.; Messripour, M.; Yousefi, M.H.; Amiri, G.R. Effect of magnetic iron oxide nanoparticles on pregnancy and testicular development of mice. Afr. J. Biotechnol. 2011, 10, 1221-1227. [CrossRef].
31. Gutaj, P.; Wender-Ozegowska, E.; Mantaj, U.; Zawiejska, A.; Brazert, J. Maternal body mass index and gestational weight gain and their association with perinatal outcome in women with gestational diabetes. Ginekol. Pol. 2011, 82, 827-833. [PubMed].
32. Godfrey, K.M.; Barker, D.J. Fetal programming and adult health. Public Health Nutr. 2001, 4, 611-624. [CrossRef] [PubMed].
33. World Health Organization (WHO). Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women; WHO Press: Geneva, Switzerland, 2012.
34. Chernoff, N.; Rogers, J.M. Supernumerary ribs in developmental toxicity bioassays and in human populations: Incidence and biological significance. J. Toxicol. Environ. Health Part B 2004, 7, 437-449. [CrossRef] [PubMed].
35. Lacey, J.V.; Chia, V.M. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009, 63, 39-44. [CrossRef] [PubMed].
36. Espindola, D.; Kennedy, K.A.; Fischer, E.G. Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia. Obstet. Gynecol. Clin. N. Am. 2007, 34, 717-737. [CrossRef] [PubMed].
37. Cooper, T.G.; Noonan, E.; von Eckardstein, S.; Auger, J.; Baker, H.W.G.; Behre, H.M.; Haugen, T.B.; Kruger, T.; Wang, C.; Mbizvo, M.T.; et al. World Health Organization reference values for human semen characteristics. Hum. Reprod. Update 2010, 16, 231-245.
38. Meistrich, M.L. Evaluation of reproductive toxicity by testicular sperm head counts. J. Am. Coll. Toxicol. 1989, 8, 551-567. [CrossRef].
39. Bourrinet, P.; Bengele, H.H.; Bonnemain, B.; Dencausse, A.; Idee, J.M.; Jacobs, P.M.; Lewis, J.M. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Investig. Radiol. 2006, 41, 313-324. [CrossRef] [PubMed].
40. Hong, J.-S.; Park, M.-K.; Kim, M.-S.; Lim, J.-H.; Park, G.-J.; Maeng, E.-H.; Shin, J.-H.; Kim, Y.-R.; Kim, M.-K.; Lee, J.-K.; et al. Effect of zinc oxide nanoparticles on dams and embryo-fetal development in rats. Int. J. Nanomed. 2014, 9, 145-157.
41. Xu, Y.; Ying, Q.; Soubantika, P.; Yuping, B. Water-soluble iron oxide nanoparticles with high stability and selective surface functionality. Langmuir 2011, 27, 8990-8997. [CrossRef] [PubMed].
42. Godbey, W.T.; Wu, K.K.; Mikos, A.G. Size matters: Molecular weight affects the efficiency of poly(ethyleneimine) as a gene delivery vehicle. J. Biomed. Mater. Res. 1999, 43, 268-275. [CrossRef].
43. Fischer, D.; Bieber, T.; Li, Y.; Elsässer, H.P.; Kissel, T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: Effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res. 1999, 16, 1273-1279. [CrossRef] [PubMed].
44. Guideline S5 (R2): Detection of toxicity to reproduction for medicinal products & toxicity to male fertility. 2005 Available online: http://122.3.253.116/attachments/article/99526/S5%28R2%29%20Step4.pdf (accessed on 14 December 2015).
45. Cima, G. AVMA guidelines for the euthanasia of animal: 2013 edition. J. Am. Vet. Med. Assoc. 2013, 242, 715-716.
46. Webb, G.N.; Byrd, R.A. Simultaneous differential staining of cartilage and bone in rodent fetuses-an alcian blue and alizarin red S procedure without glacial acetic acid. Biotech. Histochem. 1994, 69, 181-185. [CrossRef] [PubMed].